Record growth masks underlying lumpiness; execution risk on new initiatives

Q1FY27 revenue 641.6 Cr, up 119.2% YoY but down 17.3% QoQ; CFO cited favorable customer mix

YoY growth exceptional at +119%, but management refrained from FY27 guidance; Q4 was Q3 spillovers

Q1 alone grew 119% YoY; full-year guidance withheld, suggesting Q1 is not representative

Management explicitly says 25% is normalized target; current level boosted by FX tailwinds and favorable mix

Facility commissioning next month (Sept 2026); projects in various stages; no revenue visibility in Q1

2 years ago internal conviction only; now customer interest expanding pre-commissioning, projects converting. CEO: validates long-term thesis early.

FY27: 2 new advanced-stage projects entered vs. prior thinness. CEO feels "a lot better" vs. 1-2 years ago on pipeline confidence.

Shift from project-focused to account-focused, multi-year partnerships. 5-year old customers now expanding total business with Neuland vs. discrete projects.

₹203 Cr approved this quarter vs. prior historical pace. CEO: "bold moves" planned; geographic diversification (M&A or overseas organic) on agenda over 1-2 years.

Q1 EBITDA 35.5% driven by FX + mix; CEO guided to 25% as normalized. Current margin peak, not sustainable.

We aspire to 20% growth for FY27-28. Order visibility solid, destocking not factored for FY27 but beyond-year conversations ongoing.

2 new advanced-stage projects entered Q1; peptide projects also. Volumes will increase but premature to quantify revenue this year.

~3 molecules drive commercial; healthy 5-6 year visibility on them. Peptide facility commissioned next month; projects lined up at various stages.

Relative comfort, improved 1-2 years ago. Account-focused approach validating; 3-5 years will have healthy new molecules, though projects still in development so caution warranted.

5 years ago, largest molecule ₹50 Cr/year; now can visualize ₹500-1000 Cr/year molecules. Confidence from substantiated customer conversations, multi-year relationships.

Q4 was Q3 spillovers (exceptional); not a valid comparison base. Lumpiness inherent; Q1 not a normalized run-rate.

Quarter good indicator of progress; trend line clear over 10-15 quarters. Margins 25%+ target; current 35.5% helped by FX and mix. Long-term 25% plus is guidance.

Sterile API manufacturing for niche generic molecules. Gland has regulatory track record; Neuland avoids sterile facility risks; asset-light arrangement; long-term potential.

Aspiration, not binding. Order book solid, CMS commercial visible 5-6 years; development pipeline inflecting. No FY27 specific number given due to lumpiness.

CEO explicit: FX tailwinds contributed; favorable mix temporary. Expect reversion toward 25% as baseline over time.

Unit 1 expansion ₹196 Cr; peptides, R&D, sterile APIs, potential M&A/overseas organic. 3-year, 4-year horizon for capacity saturation.

~3 commercial molecules drive majority CMS revenue. CEO: "handful and not just one" but lumpiness acknowledged. Destocking, ordering pattern shifts, or molecule lifecycle transitions pose volume cliff risk.

Peptide Module 1 commissioning September 2026. Projects lined up pre-commissioning but no commercial revenue yet. FDA audit dependent; manufacturing qualification in progress. 15-year process development but commercial scale unproven.

EBITDA margin 35.5% in Q1 driven by favorable FX and customer mix. CEO explicitly guided to 25% as normalized target. Rupee strength temporary; mix shifts as commercial molecules cycle.

₹203 Cr approved this quarter; ₹121.6 Cr spent Q1. Total program ₹1,460 Cr (60% deployed). CEO flagged forward capex "much higher." Capex payoff dependent on revenue conversion in 2-3 years.

2 new advanced-stage projects entered Q1; some peptide. CEO confident but cautious ("relationships relatively new", "projects in development"). 3-5 year horizon to commercial significance means limited near-term visibility.